Pentixapharm Holding AG PTP
XETR · Germany · Health Technology
€1.850.00 (0.00%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Background: A Silent Mass Market and a Diagnostic Challenge
Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant hypertension with underlying Primary Aldosteronism.
Pentixapharm Holding AG: FDA grants "Study May Proceed" for PANDA Phase 3 Study; Intended Capital Increase with Subscription Rights in a Volume of Up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.